Skip to contentT
TELA Bio, Inc.
T
TELATELA Bio, Inc. Q3 2022 · 10-Q
Revenue$11.16M$11.16M+45.8% vs Q3 2021 Net Income-$10.71M-$10.71MN/M vs Q3 2021 EPS Diluted-$0.64-$0.64N/M vs Q3 2021 Gross Profit$7,319,000+59.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TELA Bio, Inc. · CIK 1561921 · Engraved from SEC EDGAR
Operating Cash Flowderived-$7,649,000N/M Free Cash Flowderived-$7,939,000N/M Margins · derivedGross margin65.6%+5.5 pt vs Q3 2021
Operating margin-85.0%+9.3 pt vs Q3 2021
Net margin-96.0%+12.0 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 10, 2022 · 41 d after period end